S-1* combination therapy was associated with a higher response rate and longer progression-free survival (PFS) than S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer, a new meta-analysis has found.
Triglyceride and glucose index in combination with body mass index (TyG-BMI) is an effective marker in detecting nonalcoholic fatty liver disease (NAFLD) in nonobese individuals, a new observational study has found.
Early introduction of glycyrrhizin in combination with tenofovir in the treatment of patients with severe acute exacerbation (SAE) of chronic hepatitis B is safe and effective, reducing serum transaminases rapidly in the first 2 weeks when compared with tenofovir alone, according to the results of an open-label trial.
Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres does not improve overall survival (OS) vs sorafenib in patients with locally advanced hepatocellular carcinoma (HCC), although it significantly improves tumour response and reduces adverse events (AEs), the phase III SARAH study has shown.
Nonalcoholic fatty liver diseases (NAFLD) and serum concentrations of alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP) are independent predictors of incident type 2 diabetes, a new prospective study shows.
Intrahepatic regulatory T cells (Tregs), enriched in untreated paediatric autoimmune hepatitis (pAIH) patients, are disproportionately reduced during treatment, a new study reveals. Similarly, serum concentrations of interleukin (IL)-2 also decrease during treatment.
The Asian Pacific Digestive Week (APDW) 2017, to be held in Hong Kong on 23–26 September, will examine key issues in and the future of digestive disease management in the Asia-Pacific region. Professor Justin Wu of the Chinese University of Hong Kong (CUHK), Congress President of APDW 2017 and President of the Hong Kong Society of Gastroenterology, talks to MIMS Doctor about challenges the region is facing and shares highlights of the upcoming congress.
Oral ombitasvir/paritaprevir/ritonavir and dasabuvir combination regimen is more cost-effective than standard treatment in patients with chronic genotype 1 hepatitis C virus (HCV) infection, as shown in a review.
At a recent Abbott-sponsored symposium during the 11th Liver Update 2015, Professor José Mato discussed the role of S-adenosylmethionine (SAMe) in liver diseases. The following are highlights from his talk.